{"prompt": "['Alliance A221701', '4.0', 'PATIENT REGISTRATION', '4.1', 'Investigator and Research Associate Registration with CTEP', 'Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy', 'require all individuals contributing to NCI-sponsored trials to register and renew their', 'registration annually. To register, all individuals must obtain a Cancer Therapy Evaluation', 'Program (CTEP) Identity and Access Management (IAM) account', 'at', 'In addition, persons with a registration type of Investigator', '(IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) must complete their annual', \"registration using CTEP's web-based Registration and Credential Repository (RCR) at\", 'RCR utilizes five person registration types.', 'IVR - MD, DO, or international equivalent;', 'NPIVR - advanced practice providers (e.g., NP or PA) or graduate level', 'researchers (e.g., PhD);', 'AP - clinical site staff (e.g., RN or CRA) with data entry access to CTSU', 'applications such as the Roster Update Management System [RUMS], OPEN,', 'Rave, acting as a primary site contact, or with consenting privileges;', 'Associate (A) - other clinical site staff involved in the conduct of NCI-', 'sponsored trials; and', 'Associate Basic (AB) - individuals (e.g., pharmaceutical company', 'employees) with limited access to NCI-supported systems.', 'RCR requires the following registration documents:', 'Documentation Required', 'IVR', 'NPIVR', 'AP', 'A', 'AB', 'FDA Form 1572', 'Financial Disclosure Form', 'NCI Biosketch (education, training, employment,', 'license, and certification)', 'GCP training', 'Agent Shipment Form (if applicable)', 'CV (optional)', 'An active CTEP-IAM user account and appropriate RCR registration is required to access all', 'CTEP and Cancer Trials Support Unit (CTSU) websites and applications. In addition, IVRs and', 'NPIVRs must list all clinical practice sites and Institutional Review Boards (IRBs) covering', 'their practice sites on the FDA Form 1572 in RCR to allow the following:', 'Addition to a site roster;', 'Assign the treating, credit, consenting, or drug shipment (IVR only) tasks in', 'OPEN;', 'Act as the site-protocol Principal Investigator (PI) on the IRB approval; and', '16', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', 'Assign the Clinical Investigator (CI) role on the Delegation of Tasks Log', '(DTL).', 'In addition, all investigators acting as the Site-Protocol PI (investigator listed on the IRB', 'approval), consenting/treating/drug shipment investigator in OPEN, or as the CI on the DTL', 'must be rostered at the enrolling site with a participating organization.', 'Additional', 'information', 'is', 'located', 'on', 'the', 'CTEP', 'website', 'at', 'For questions, please contact the', 'RCR Help Desk by email at', '4.2', 'CTSU Site Registration Procedures', 'Permission to view and download this protocol and its supporting documents is restricted and is', 'based on person and site roster assignment housed in the CTSU Regulatory Support System', '(RSS).', 'This study is supported by the NCI Cancer Trials Support Unit (CTSU).', 'IRB Approval', 'For CTEP and Division of Cancer Prevention (DCP) studies open to the National Clinical Trials', 'Network (NCTN) and NCI Community Oncology Research Program (NCORP) Research Bases', 'after March 1, 2019, all U.S.-based sites must be members of the NCI Central Institutional', 'Review Board (NCI CIRB). In addition, U.S.-based sites must accept the NCI CIRB review to', 'activate new studies at the site after March 1, 2019. Local IRB review will continue to be', 'accepted for studies that are not reviewed by the CIRB, or if the study was previously open at', 'the site under the local IRB. International sites should continue to submit Research Ethics Board', '(REB) approval to the CTSU Regulatory Office following country-specific regulations.', 'Sites participating with the NCI CIRB must submit the Study Specific Worksheet for Local', 'Context (SSW) to the CIRB using IRBManager to indicate their intent to open the study locally.', \"The NCI CIRB's approval of the SSW is automatically communicated to the CTSU Regulatory\", 'Office, but sites are required to contact the CTSU Regulatory Office at', 'to establish site preferences for applying NCI CIRB approvals', 'across their Signatory Network. Site preferences can be set at the network or protocol level.', 'Questions about establishing site preferences can be addressed to the CTSU Regulatory Office', 'by email or calling', 'Sites using their local IRB or REB, must submit their approval to the CTSU Regulatory Office', 'using the Regulatory Submission Portal located in the Regulatory section of the CTSU website.', 'Acceptable documentation of local IRB/REB approval includes:', 'Local IRB documentation;', 'IRB-signed CTSU IRB Certification Form; and/or', 'Protocol of Human Subjects Assurance Identification/IRB Certification/Declaration', 'of', 'Exemption Form.', 'In addition, the Site-Protocol Principal Investigator (PI) (i.e. the investigator on the IRB/REB', 'approval) must meet the following criteria in order for the processing of the IRB/REB approval', 'record to be completed:', 'Holds an active CTEP status;', 'Rostered at the site on the IRB/REB approval (applies to US and Canadian', 'sites only) and on at least one participating roster;', '17', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}